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Abstract
Objective: Somatotroph adenomas are typically recognized when they secrete GH excessively and cause
acromegaly.Both‘silent’somatotrophadenomas(immunohistochemicalevidenceofGHexcesswithout
biochemical or clinical evidence) and ‘clinically silent’ somatotroph adenomas (immunohistochemical
and biochemical evidence but no clinical evidence) have occasionally been reported. The relative
frequency of each presentation is unknown. The goal of this study was, therefore, to determine the
frequency of clinically silent somatotroph adenomas, a group that is potentially recognizable in vivo.
Design: We retrospectively identiﬁed 100 consecutive patients who had surgically excised and
histologically conﬁrmed pituitary adenomas.
Methods: Each pituitary adenoma was classiﬁed immunohistochemically by pituitary cell type.
Somatotroph adenomas were further classiﬁed as ‘classic’ (obvious clinical features of acromegaly and
elevated serum IGF1), ‘subtle’ (subtle clinical features of acromegaly and elevated IGF1), ‘clinically
silent’ (no clinical features of acromegaly but elevated IGF1), and ‘silent’ (no clinical features of
acromegaly and normal IGF1).
Results: Of the 100 consecutive pituitary adenomas, 29% were gonadotroph/glycoprotein, 24%
somatotroph,18%nullcell,15%corticotroph,6%lactotroph,2%thyrotroph,and6%notclassiﬁable.Of
the24patientswithsomatotrophadenomas,classicaccountedfor45.8%,subtle16.7%,clinicallysilent
33.3%, and silent 4.2%.
Conclusions: Clinically silent somatotroph adenomas are more common than previously appreciated,
representing one-third of all somatotroph adenomas. IGF1 should be measured in all patients with a
sellarmass,becauseidentiﬁcationofamassasasomatotrophadenomaexpandsthetherapeuticoptions
and provides a tumor marker to monitor treatment.
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Introduction
Somatotroph adenomas (GH producing adenomas,
somatotropinomas) are typically recognized when they
secrete GH excessively and cause the clinical syndrome
ofacromegaly. Thisrecognition not only identiﬁesa sellar
mass as a somatotroph adenoma but also expands the
therapeutic options. Occasional reports in the literature
also describe ‘silent somatotroph adenomas,’ referring to
adenomas that can be identiﬁed as somatotroph adeno-
mas by positive immunohistochemical staining for GH,
but are not associatedwith clinicalevidence ofGH excess.
Some of these adenomas are totally silent, in that they
are not associated with either clinical manifestations of
GH excess or elevated serum concentrations of GH or
IGF1(1–5).Othersare‘clinicallysilent’,inthatGHand/or
IGF1 serum concentrations are elevated, even though
they are not associated with clinical manifestations of
GHexcess(5–14).Thegoalofthisstudywastodetermine
the frequency of clinically silent somatotroph adenomas,
a group that is potentially recognizable biochemically
in vivo. To do so, we reviewed the records of 100 con-
secutive surgically excised pituitary adenomas. Of those
identiﬁed immunohistologically as somatotroph adeno-
mas, we reviewed the clinical records and categorized
the patients according to a spectrum of GH expression
as ‘classic’, ‘subtle’, ‘clinically silent’, or ‘silent’.
Subjects and methods
Patient identiﬁcation
We retrospectively identiﬁed 100 consecutive patients
who underwent resection of pituitary adenomas at
the Hospital of the University of Pennsylvania between
June 1, 2007 and November 2, 2009 by performing
a query of the laboratory information system (Cerner
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included if our reviewof the excised tissue conﬁrmed the
diagnosis of a pituitary adenoma. The Institutional
Review Board of the University of Pennsylvania
approved the study.
Tissue handling, histology and
immunohistochemistry
Fresh tissue from each adenoma was ﬁxed in 10%
formalin for a period of 6–72 h. Routine processing and
embedding into parafﬁn were performed according to
standard protocols. Sections (4 mm thick) were stained
with hematoxylin and eosin (H&E) or were used for
immunohistochemical analysis. Each adenoma was
immunohistochemically stained for six pituitary hor-
mones: GH, prolactin, ACTH, FSH, LH, and TSH. The
antibodies (Dako, Carpinteria, CA, USA) used were
rabbit polyclonal anti-GH at 1:700 dilution (Dako,
A0570), rabbit polyclonal anti-prolactin at 1:250
(Dako, A0569), mouse monoclonal anti-ACTH at
1:2000 (Dako, M3501, clone 02A3), mouse mono-
clonal anti-FSHb subunit at 1:40 (Dako, M3504),
mouse monoclonal anti-LHb subunit at 1:300 (Dako,
M3502, clone C93), and mouse monoclonal anti-TSHb
subunit at 1:400 (Dako, M3503, clone 0042). Staining
was performed on a Bond Max Autostainer (Leica
Microsystems, Buffalo Grove, IL, USA) after antigen
retrieval. Hematoxylin (blue) counterstaining was
performed to allow the visualization of cell nuclei. The
substrate chromogen, 30,3-diamobenzidine, was used to
visualize the targeted complex via a brown precipitate.
All somatotroph adenomas were further analyzed by
cytokeratin staining with mouse monoclonal anti-
CAM5.2 undiluted (BD Pharmagen 349205, Franklin
Lakes, NJ, USA), using the same immunohistochemical
protocol.
Adenoma classiﬁcation
A neuropathologist (J B) reviewed H&E and immuno-
histochemical stains and categorized the adenomas
based on the type, intensity, and distribution of
hormone expression. Adenomas that expressed GH
were categorized as somatotrophs; prolactin as lacto-
trophs; ACTH as corticotrophs; FSH and/or LH as
gonadotrophs; FSH, LH, and TSH as glycoprotein; TSH
as thyrotrophs; and, if there was no staining, null cell.
Staining was evaluated in a semi-quantitative manner,
using three grades of positivity: strong, moderate, and
weak. The distribution of staining was graded as diffuse
(present throughout the adenoma), scattered (present
in a small subset of adenoma cells, distributed
throughout the adenoma), and focal (present in the
majority of cells in one or more geographic areas of the
adenoma). Adenomas that showed strong or moderate
staining (diffuse, scattered or focal) for one hormone,
but no staining for the other ﬁve hormones, were
classiﬁed in the category associated with the expressed
hormone (e.g. somatotroph for adenomas that showed
positivity only for GH). Adenomas that showed not only
strong staining for one hormone but also weak staining
(diffuse or scattered) for one or more other hormones
were classiﬁed by the dominant hormone. Glycoprotein
adenomas (concurrent positivity for FSH, LH, and TSH),
and in some cases gonadotroph adenomas (those
showing positivity for both FSH and LH), were identiﬁed
by the positive staining of the characteristic set of
multiple hormones, and negative staining for the rest
of the immunohistochemical panel. Adenomas that
did not exhibit staining for any of the hormones, or
only weak scattered staining, were classiﬁed as null cell
adenomas. Lack of expression of all hormones was
conﬁrmed at the time of review by repeat immuno-
histochemical stainingof the tissue.It was observed that
two adenomas were almost entirely necrotic, precluding
immunohistochemical categorization and one ade-
noma, which showed strong diffuse staining for ACTH
and GH and moderate scattered stainingof LH and TSH,
was considered indeterminate by immunohistochemical
classiﬁcation. Adenomas that strongly expressed both
GH and a second hormone were classiﬁed as somato-
trophs for the purposes of this study.
The cytokeratin staining pattern of the somatotroph
adenomas was evaluated in 300 cells of each somato-
troph adenoma. The individual cells were classiﬁed as
having a perinuclear pattern, dot pattern, or transi-
tional pattern, as described in Obari et al. (15). The
adenomas were then classiﬁed as densely granulated,
sparsely granulated, and transitional based on the
proportions of the three staining types. Adenomas were
classiﬁed as densely granulated if O70% of cells
exhibited a perinuclear pattern or !8% exhibited a
dot pattern, irrespective of the percentage of cells that
exhibited a transitional pattern. Adenomas were
classiﬁed as sparsely granulated if O70% of cells
exhibited a dot pattern, irrespective of the percentage
of cells with a transitional pattern. Adenomas were
classiﬁed as intermediateif theydid not ﬁt into either the
densely or the sparsely granulated categories.
Clinical and biochemical characterization of
patients with somatotroph adenomas
We reviewed the clinical records of patients with
somatotroph adenomas and extracted demographic
data, clinical characteristics, and serum IGF1 concen-
trations. We determined the presence of what we
deﬁned as ‘highly speciﬁc’ and ‘associated’ features of
acromegaly. We deﬁned highly speciﬁc features as those
usually seen only in patients with acromegaly (growth
of hands, feet, head or jaw in adulthood, frontal bossing,
prognathism, large tongue, and wide hands and feet)
and deﬁned associated features as those seen in the
general population but more commonly in acromegaly
(carpal tunnel syndrome, obstructive sleep apnea, type
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classiﬁed patients as having typical clinical features of
acromegaly if they exhibited two or more highly speciﬁc
features; mild features if they exhibited one highly
speciﬁc feature or three associated features; and no
features if they exhibited no highly speciﬁc features and
not more than two associated features.
Finally, we deﬁned the spectrum of GH expression of
somatotroph adenomas by classifying each adenoma
(Table 1) as ‘classic’ (typical clinical features of
acromegaly and elevated serum IGF1), ‘subtle’ (mild
clinical features of acromegaly and elevated IGF1),
‘clinically silent’ (no clinical features of acromegaly but
elevated IGF1), or ‘silent’ (no clinical features of
acromegaly and normal IGF1) based on the com-
bination of clinical characteristics, serum IGF1 concen-
tration, and immunohistochemical staining.
Results
Classiﬁcation of pituitary adenomas
Of the 100 consecutive pituitary adenomas, the cell type
by immunohistochemistry was gonadotroph/glyco-
protein in 29%, somatotroph in 24%, null cell in 18%,
corticotroph in 15%, lactotroph in 6%, thyrotroph in
2%, and not classiﬁable in 6% (Table 2). The two
adenomasthatstainedstronglyforbothGHandprolactin
(somatomammotroph adenomas) and one adenoma that
stained strongly for both GH and ACTH were classiﬁed
as somatotroph adenomas for the purpose of this study.
Classiﬁcation of somatotroph adenomas
Of the 24 patients who had somatotroph adenomas, 11
(45.8%) were considered to have classic somatotroph
adenomas, four (16.7%) subtle somatotroph adenomas,
eight (33.3%) clinically silent somatotroph adenomas,
and one (4.2%) a silent somatotroph adenoma
(Table 3). The clinical assessment of each of the eight
patients categorized as having a clinically silent
somatotroph adenoma was made by an experienced
endocrinologist. The mean serum IGF1 concentrations
were 768 ng/ml in the classic, 533 ng/ml in the subtle,
and 451 ng/ml in the clinically silent adenomas.
Two of the classic somatotroph adenomas co-secreted
prolactin and one of the clinically silent somatotroph
adenomas co-secreted ACTH.
Characteristics of patients with clinically
silent somatotroph adenomas
The characteristics of the eight patients with clinically
silent somatotroph adenomas are shown in Table 4.
There was no clear predilection for gender or age. Of the
eight patients, four had no associated clinical features of
acromegaly, two had only hypertension, and two had
hypertension and another associated feature. All
patients, by deﬁnition, had serum IGF1 concentrations
above the age- and gender-adjusted normal range; three
had concentrations more than twice the upper limit of
normal. Duplicate determinations of IGF1 were pre-
operatively available for three patients and in each
conﬁrmed the elevation. Serum IGF1 values were
postoperatively available for seven patients and had
decreased to normal in ﬁve patients; one patient whose
value was elevated postoperatively demonstrated a
decrease in IGF1 after administration of lanreotide.
Each of the eight patients had either conﬁrmation of the
elevated IGF1 value preoperatively and/or a decrease in
IGF1 to normal in response to surgery or lanreotide. All
patients had macroadenomas. Of the eight patients, two
underwent surgery because of neurological symptoms,
two because of an enlarging mass by serial imaging, and
four because of the patients’ anxiety about the presence
of a sellar mass in the absence of symptoms.
Immunohistochemical staining of clinically
silent somatotroph adenomas
Figure 1 shows representative sections of the eight
clinically silent somatotroph adenomas and illustrates
that all express GH strongly, some diffusely, and others
scattered. Adenomas from patients 17, 40, 48, and 70
show a strong, diffuse staining pattern, and adenomas
from patients 45, 54, and 62 show a strong scattered
pattern. The tissue available for histological analysis
from patient 52 consisted primarily of blood, but the
limited number of viable adenoma cells shows strong
GH staining in the majority. The range of the strength
and patterns of GH staining in the adenomas from
patients who were classiﬁed as clinically silent was not
obviously different from those of the patients classiﬁed
as classic.
In addition, the cytokeratin staining pattern of the
clinically silent adenomas, as an indicator of subtype,








Classic Typical Elevated Positive
Subtle Mild Elevated Positive
Clinically silent None Elevated Positive
Silent None Normal Positive
Table 2 Immunohistochemical classiﬁcation of 100
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subtypes. Speciﬁcally, three classic somatotroph adeno-
mas were classiﬁed as densely granulated, three as
sparsely granulated, four as intermediate type, and one
had insufﬁcient remaining tissue to stain. Of the subtle
somatotroph adenomas, none was densely or sparsely
granulated, three were intermediate, and one had
insufﬁcient tissue to stain. Of the clinically silent
somatotroph adenomas, one was densely granulated,
three were sparsely granulated, two were intermediate,
and two had too little tissue to stain. The single silent
adenoma was intermediately granulated.
Discussion
Of the 100 consecutive pituitary adenomas at a single
institution that were excised surgically and conﬁrmed
histologically, 24 were identiﬁed immunohistochemi-
cally as somatotroph adenomas. Review of the clinical
and biochemical characteristics of these 24 somato-
troph adenomas resulted in characterizing 45.8% as
presenting with classic acromegaly, 16.7% as having
subtle acromegaly, 33.3% as clinically silent, and 4.2%
as totally silent. The surprising ﬁnding was the
substantial proportion – one-third – that presented as
‘clinically silent,’ in that the patients harboring those
adenomas could not be recognized as even subtly
acromegalic by experienced endocrinologists.
Somatotroph adenomas in which there is bio-
chemical and immunohistochemical evidence of GH
excess in the absence of clinical manifestations of
acromegaly were ﬁrst reported in 1985 (13).I tw a s
observed that two women who had no clinical features
of acromegaly but who did have non-suppressible serum
GH concentrations had pituitary adenomas that, after
excision, showed immunohistochemical staining for
GH. The term ‘clinically silent somatotroph adenoma’
was ﬁrst used 2 years later in describing three women
with non-suppressible serum GH concentrations and
positive GH staining of the excised adenoma tissue (7).
The largest previous series of clinically silent somato-
troph adenomas described a total of 17 patients who
had silent somatotroph adenomas, of which four were
clinically silent (5). These four patients had no clinical
manifestations of acromegaly but did have elevated
basal serum GH concentrations that did not suppress
after ingestion of glucose. These four patients rep-
resented only 1.6% of the total number of 251
somatotroph adenomas in that series. The reason for
the much lower frequency in that study compared with
this study is not clear, although it might be the result of
different criteria for determining GH excess.
The explanation for the lack of clinical manifestations
of some somatotroph adenomas compared with the
obvious manifestations in others, even though both
exhibit elevated GH and/or IGF1 concentrations, is not
certain. Each patient with a clinically silent somato-
troph adenoma was examined by an experienced
endocrinologist, reducing the likelihood that clinical
features were present, but undetected, although even
the most experienced endocrinologist may miss subtle
features of acromegaly. Another possible explanation is
a lesser duration of excessive GH secretion, but some
reports describe such patients in whom excessive GH
secretion has been documented for several years (9, 10).
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45 55 M HTN 264
c, 309
c – 87–225 ‘Macroadenoma’
48 77 M HTN, T2DM 362
d 66
d 35–213 28!24!24
52 35 F None 371
c 230
c 126–291 10!9!12








70 74 F HTN, polyps 487
c 246
c 25–171 18!12!17
HTN, hypertension and T2DM, type 2 diabetes mellitus.
aNormal ranges for serum IGF1 concentration are speciﬁc for age and gender.
bDimensions: cephalocaudad!transverse!anterio–posterior.
cPerformed at quest diagnostics laboratories.
dPerformed at ARUP laboratories.
ePostoperative.
fIFG-1 value post-administration of lanreotide.






Clinically silent 8 33.3
Silent 1 4.2
Total 24 100
aDeﬁnitions of adenoma types given in text.
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or secretion of biologically inactive GH explain lack of
clinical manifestations are refuted by ﬁnding clear
elevation of serum IGF1 in all of the patients presented
here. The most likely explanation of the differential GH
expression is differential GH secretion, as judged by
differential IGF1 concentrations. Although three of
the eight patients with clinically silent adenomas
reported here had serum IGF1 concentrations more
than twice the upper limit of normal, the mean IGF1
concentrations were higher in those patients catego-
rized as classic and subtle than in those classiﬁed as
clinically silent.
Because previous studies have reported possible
associations between sparsely and densely granulated
somatotroph adenomas and various biological features,
such as size, aggressiveness, and propensity to respond
to a somatostatin analog (15, 16), we assessed all of the
somatotroph adenomas for this characteristic indirectly
by the pattern of cytokeratin immunostaining. We
found no obvious differences between the cytokeratin
staining pattern of clinically silent adenomas and those
of the other clinical subtypes, although the number of
somatotroph adenomas was relatively small for sub-
group analysis.
This study ascertains systematically the frequency of
clinically silent somatotroph adenomas among all
somatotroph adenomas and among consecutive pitu-
itary adenomas that were histologically and immuno-
histochemically characterized. A limitation of the
ﬁndings is that the entire population of patients was
restricted to those who had surgery, a necessity to
conﬁrm the diagnosis of a somatotroph adenoma
immunohistochemically. Another limitation is that the
clinical assignments were retrospectively made,
although this limitation is mitigated by speciﬁc
documentation by experienced endocrinologists of lack
of acromegalic features in each of the eight patients
with clinically silent adenomas.
Although GH suppressibility was not tested, IGF1
elevation is rarely seen in the presence of normal GH
suppressibility (17). Importantly, ﬁve of the seven
patients had a decrease in IGF1 to normal after
resection of their somatotroph adenomas and one
patient who had an elevated value postoperatively
exhibited a decrease to normal in response to lanreotide.
All eight patients had either a conﬁrmation of their
elevated IGF1 concentration preoperatively and/or a
decrease in IGF1 in response to surgery or lanreotide,
strongly suggesting that each adenomawas the cause of
that patient’s elevated IGF1. Similar analyses should be
performed in other surgical series, however, to
determine whether the current results are conﬁrmed.
The clinical signiﬁcance of ﬁnding that a third of all
somatotroph adenomas are clinically nonfunctioning is
that in this substantial fraction of patients, an otherwise
unidentiﬁable sellar mass can be recognized as a
somatotroph adenoma merely by measurement of the
serum concentration of IGF1. This recognition expands
the therapeutic options to include pharmacological
treatment and also provides a tumor marker to follow to
monitor the efﬁcacy of treatment. This study supports
the recommendation to measure the serum concen-
tration of IGF1 in all patients who have a sellar mass.
Declaration of interest
P J Snyder receives research support from Novartis and Tercica. The
other authors have no conﬂicts of interest to disclose.
Funding
This research did not receive any speciﬁc grant from any funding
agency in the public, commercial, or not-for-proﬁt sector.
Acknowledgements
We thank Drs John Lee and Eric Zager for allowing us to review the





Figure 1 Representative images of immunohistochemical staining
for GH of adenomas from eight patients with clinically silent
somatotroph adenomas (200! magniﬁcation). All show strong
staining,some diffuse,and othersscattered.Subjectnumbersin the
upper left corners correspond to those in Table 4.
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